<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941680</url>
  </required_header>
  <id_info>
    <org_study_id>13/B/04</org_study_id>
    <secondary_id>2013-A00327-38</secondary_id>
    <nct_id>NCT01941680</nct_id>
  </id_info>
  <brief_title>High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant</brief_title>
  <acronym>ATLL-HR-01</acronym>
  <official_title>Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leukaemia (T-cell Lymphoma/Leukaemia) Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and
      Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI). For patients younger than
      65 years old, an allogeneic donor is searching out. Patients included at relapse and with
      lymphoma clinico-biological subtype also receive chemotherapy (CT). Responses are assessed
      during ZPI+/-CT and eligible patients (depending on age, comorbidities and response criteria)
      receive allogeneic transplant. Patient follow-up is planned for 3 years old
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with relapse</measure>
    <time_frame>Up to 3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of presence of gene expression of Tax and HBZ confirmed by Rt-PCR</measure>
    <time_frame>1 year</time_frame>
    <description>The titrations of genes are performed at month 12, month 24 and month 36</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>T-cell Lymphoma</condition>
  <condition>Leukaemia</condition>
  <arm_group>
    <arm_group_label>ZPI</arm_group_label>
    <description>Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPI+CHOP-21</arm_group_label>
    <description>Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
CHOP-21 Day1 = day 21 (3 cycles)
Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.
day 2-Day 5 Prednisone
1mg/kg/day PO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPI +DHAP-21</arm_group_label>
    <description>Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Populations of French Caribbean Islands and Guyana with ATLL-HR. .
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;18 years old and ≤ 75 years old, with ATLL-HR who signed informed consent.

        Exclusion Criteria:

          -  Pregnant or nursing women are not eligible; neither are women of childbearing
             potential unless using effective contraception as determined by the patient's
             physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Côme MENIANE, MD</last_name>
    <email>Jean-Come.Meniane@chu-fortdefrance.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Pinteà Pitre/Abymes</name>
      <address>
        <city>Pointe à Pitre</city>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tawfik CHALABI, MD</last_name>
      <email>tawfik.chalabi@chu-guadeloupe.fr</email>
    </contact>
    <investigator>
      <last_name>Tawfik CHALABI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort de France</city>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Côme MENIANE</last_name>
      <email>Jean-Come.Meniane@chu-fortdefrance.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mickaëlle ROSE</last_name>
      <phone>+596596592623</phone>
      <email>mickaelle.rose@chu-fortdefrance.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Côme MENIANE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Guadeloupe</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

